Russia announces vaccine that can completely destroy tumors

A cancer vaccine invented in Russia can completely destroy tumors.

According to the Russian Ministry of Health, after preclinical trials showing high safety and effectiveness, the cancer vaccine is expected to be announced and conducted clinical trials with research teams in early 2025. According to the head of oncology at the Russian Ministry of Health, Andrey Kaprin, EnteroMix - the name of the new revolutionary Russian vaccine - is a combination of four non-pathogenic viruses, that is, artificial viruses. They are capable of destroying malignant cells, while activating the patient's anti-cancer immunity. With the success of preclinical trials, the Russian Ministry of Health and the Federal Health Service (Roszdravnadzor) have granted permission to recruit research teams to conduct clinical trials, aiming to treat lung, kidney, pancreatic cancer and malignant tumors.

Illustration photo. Source: Barlaman Today

Russia’s announcement that it has developed a vaccine that can completely destroy tumors could have important implications for the medical and cancer research fields. If the vaccine is truly effective, it could mark a major step forward in cancer treatment, opening up hope for millions of patients around the world. A vaccine that can destroy tumors could help reduce cancer mortality, improve quality of life, and prolong life for patients. If the vaccine can replace or complement current treatments such as chemotherapy and radiotherapy, the cost of cancer treatment could be reduced, making health care more accessible. The announcement could spur further research and development in the field of cancer vaccines and treatments, leading to new discoveries and improvements. Such a vaccine could bring hope not only to patients but also to their families and communities, helping to reduce the anxiety and fear associated with cancer. The announcement could spur competition among countries to develop cancer treatments, leading to rapid innovation and improvement in the field. However, it is important to note that claims of vaccine efficacy need to be verified through rigorous clinical trials before they can be widely used. Russian patients aged 18 to 75 will be able to take part in the trial as early as 2025. A dose of the cancer vaccine will cost the state about 300,000 rubles ($3,000), but will be provided free of charge to patients in Russia.

EnteroMix is ​​a state-funded project, with three participating development units including the Gamaleya National Research Center for Epidemiology and Microbiology, the Blokhin Cancer Center and the Hertzen Cancer Research Institute. According to the inventors, the vaccine is created on the basis of mRNA technology, which has been used by drug manufacturers Pfizer and Moderna to produce COVID-19 vaccines./.

Bui Tue